xml version="1.0" encoding="UTF-8"?


C\_2018205EN.01003101.xml


| | | | |
| --- | --- | --- | --- |
| 14.6.2018 | EN | Official Journal of the European Union | C 205/31 |

---

Prior notification of a concentration

(Case M.8916 — JIC/TAHL/Australia Nature’s Care Biotech)

Candidate case for simplified procedure

(Text with EEA relevance)

(2018/C 205/07)

1.

On 5 June 2018, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [(1)](#ntr1-C_2018205EN.01003101-E0001).

This notification concerns the following undertakings:

| | |
| --- | --- |
| — | China Jianyin Investment Limited (‘JIC’, China), |

| | |
| --- | --- |
| — | Tamar Alliance Health Limited (‘TAHL’, Cayman Islands), |

| | |
| --- | --- |
| — | Australia Nature’s Care Biotech Co., Ltd.A (‘ANCB’, Australia) controlled by Alex Wu and Jina Chen. |

JIC and TAHL acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of ANCB.

The concentration is accomplished by way of purchase of shares.

2.

The business activities of the undertakings concerned are:

—   for JIC: integrated investment group focused on equity investments, with financial service, industrial manufacturing, culture and consumption and information technology as its four main investment areas,

—   for TAHL: investment vehicle dedicated to investing in consumer and healthcare sectors,

—   for ANCB: one of Australia's leading vitamins and supplements companies, active in manufacturing, marketing, selling, distributing, and exporting vitamins and supplements products and other healthcare products (including, skincare products and baby care products) across Australia, China and Taiwan.

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 [(2)](#ntr2-C_2018205EN.01003101-E0002) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.8916 — JIC/TAHL/Australia Nature’s Care Biotech

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

| |
| --- |
| Email: COMP-MERGER-REGISTRY@ec.europa.eu |
| Fax +32 22964301 |
| Postal address: |
| European Commission |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

---

[(1)](#ntc1-C_2018205EN.01003101-E0001)  [OJ L 24, 29.1.2004, p. 1](http://publications.europa.eu/resource/oj/JOL_2004_024_R_TOC) (the ‘Merger Regulation’).

[(2)](#ntc2-C_2018205EN.01003101-E0002)  [OJ C 366, 14.12.2013, p. 5](http://publications.europa.eu/resource/oj/JOC_2013_366_R_TOC).

---